Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Mild Intermittent Asthma

Conditions

Mild Intermittent Asthma

Trial Timeline

Jul 1, 2008 → Dec 1, 2008

NCT ID

NCT00716963

About Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg

Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg is a approved stage product being developed by AstraZeneca for Mild Intermittent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00716963. Target conditions include Mild Intermittent Asthma.

What happened to similar drugs?

7 of 16 similar drugs in Mild Intermittent Asthma were approved

Approved (7) Terminated (2) Active (8)

✅Aricept (donepezil hydrochloride) + placeboEisaiApproved

✅Donepezil HClEisaiApproved

✅ElagolixAbbVieApproved

✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ElidelBayerApproved

✅Osilodrostat (Isturisa)RecordatiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00716963	Approved	Completed	Jul 1, 2008	Dec 1, 2008	Mild Intermittent Asthma

Competing Products

20 competing products in Mild Intermittent Asthma

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	32
Ranirestat + Placebo	Eisai	Phase 2/3	38
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	43
Donepezil HCl	Eisai	Approved	43
Donanemab + Aducanumab	Eli Lilly	Phase 3	40
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	35
Elagolix	AbbVie	Approved	35
AZD1446 + Placebo	AstraZeneca	Phase 2	35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	29
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	35
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	40
MK-8931	Merck	Phase 1	29
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	32
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	43
LCZ696 + Sildenafil	Novartis	Phase 2	35
QCZ484 + Placebo	Novartis	Phase 1	29
Rivastigmine Patch	Novartis	Approved	43
AFQ056	Novartis	Phase 1	29
Canakinumab	Novartis	Phase 2	27